How to Buy Alnylam Pharmaceuticals Stock (ALNY)

Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 2,230 staff and has a trailing 12-month revenue of around $3.2 billion.

Our top picks for where to buy Alnylam Pharmaceuticals stock

Top pick for stock bonuses

Go to site

• Trade stocks, options, ETFs, mutual funds, alternative asset funds
• $0 commission on stocks, ETFs and options with no options contract fees
• Get up to $1,000 in stock when you open and fund a new account within 45 days
• Access to a financial planner

Disclaimer

Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.

Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.

Up to 2% match

Go to site

• Trade stocks, ETFs, options, futures and bonds all in one place
• $0 commissions on stocks, ETFs and equity options, with low contract fees
• Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.

Top pick for simple, worldwide trading

Go to site

• Trade stocks, ETFs, mutual funds, options and cryptocurrency
• Worldwide stock and options trading
• Commission-free stocks, ETFs and no transaction fee mutual funds
• Invest with as little as $1

Buy Alnylam Pharmaceuticals stock from these online trading platforms

{"userFilters":[{"config":{"MULTISELECT":true,"VALUES":"Brokerage,IRA,Education (529),Custodial,Other,Joint brokerage,Trust,Margin, Junior Roth IRA, Stock picking, Financial advisor,Kids investing,Alternative investing,Options,Market analysis,Self-directed IRA"},"dataSelector":{"recordType":"product","fieldCode":"DETAILS.ACCOUNT_TYPE"},"dataType":"TEXT","label":"Account type","order":null},{"config":{"MULTISELECT":true,"VALUES":"Stocks,Bonds,Options,Mutual funds,ETFs,Cryptocurrency,Real estate,Currencies,Gold\/Commodities,Art,CDs,Futures,Forex,Other,Alternatives,Savings,Investments,Retirement,Treasury Bills,Wine,Whiskey, Event contracts,Collectibles,Private credit, Venture capital,Annuities,Insurance, High-yield cash account, N\/A, Precious metals, Investment funds, Private equity, Tax liens\/deeds, Money market funds, Financial advisor marketplace"},"dataSelector":{"recordType":"product","fieldCode":"DETAILS.ASSET_TYPES"},"dataType":"TEXT","label":"Asset types","order":null},{"config":{"MULTISELECT":true,"VALUES":"Roth, Traditional, SEP, Spousal, Rollover, Beneficiary Traditional, Beneficiary Roth, Gold Traditional IRA, Gold Roth IRA, Custodial, SIMPLE, Self-directed, Inherited, Junior Roth IRA, Self-Directed IRA, Checkbook IRA, Solo 401(k), SEP IRA"},"dataSelector":{"recordType":"product","fieldCode":"DETAILS.IRA_ACCOUNT_TYPE"},"dataType":"TEXT","label":"Retirement account types","order":null},{"config":{},"dataSelector":{"recordType":"product","fieldCode":"FEES.FEE_TRADE_STOCK"},"dataType":"MONEY","label":"Stock trade fee","order":null},{"config":{},"dataSelector":{"recordType":"product","fieldCode":"REQUIREMENTS.MIN_DEPOSIT"},"dataType":"MONEY","label":"Minimum deposit to open","order":null},{"config":{},"dataSelector":{"recordType":"product","fieldCode":"REQUIREMENTS.MIN_TREASURY_BILLS_DEPOSIT"},"dataType":"MONEY","label":"Minimum Treasury Bills investment","order":null}],"niche":{"currencySymbol":"$","decimalPoint":".","decimalPlaces":"2","thousandsSeparator":",","filterBoundsMap":{"product.DETAILS.ACCOUNT_TYPE":null,"product.DETAILS.ASSET_TYPES":null,"product.DETAILS.IRA_ACCOUNT_TYPE":null,"product.FEES.FEE_TRADE_STOCK":{"minimum":"0","maximum":"4.95"},"product.REQUIREMENTS.MIN_DEPOSIT":{"minimum":"0","maximum":"1000000"},"product.REQUIREMENTS.MIN_TREASURY_BILLS_DEPOSIT":{"minimum":"100","maximum":"1000"}}},"prefilled":false,"experimental":false}

12 of 12 results

Finder Score	Available asset types	Stock trade fee	Minimum deposit	Cash sweep APY	bullet point infobox
Promoted Finder score 9.4 Excellent Robinhood	Finder score 9.4 Excellent	Stocks, Options, ETFs, Cryptocurrency, Futures, Event contracts, High-yield cash account	$0	$0	3.50%	Get a free stock when you successfully sign up and link your bank account. T&Cs apply.	Trade stocks, options, crypto and more, with advanced trading tools, fractional shares and exclusive perks for Gold members.	Go to site More info	loading
Promoted Finder score 8.2 Great Zacks Trade	Finder score 8.2 Great	Stocks, Bonds, Options, Mutual funds, ETFs, CDs	$0.01	$250	2.83%	Leverage powerful trading tools and low margin rates to trade stocks, options, ETFs, mutual funds and bonds.	Go to site More info	loading
Promoted Finder score 9 Excellent Public.com	Finder score 9 Excellent	Stocks, Bonds, Options, ETFs, Cryptocurrency, Investments, Retirement, Treasury Bills, High-yield cash account	$0	$0	3.6%	Get up to $10,000 and transfer fees covered when you move your portfolio to Public. T&Cs apply.	Build a diversified portfolio of stocks, bonds, options, ETFs and crypto, with a high-yield cash account and options contract rebates.	Go to site More info	loading
Finder score 9 Excellent SoFi Active Invest	Finder score 9 Excellent	Stocks, Options, Mutual funds, ETFs, Alternatives	$0	$0	0.01%	Get up to $1,000 in stock when you open and fund a new account. T&Cs apply.	Trade stocks, ETFs, and options with zero commissions, invest in IPOs or automate your portfolio, with exclusive perks available through SoFi Plus.	Go to site More info	loading
Finder score 9.4 Excellent Webull	Finder score 9.4 Excellent	Stocks, Bonds, Options, ETFs, Futures, Money market funds	$0	$0	3.60%	Deposit or transfer $100,000+ to earn a 4% Match Bonus, or $2,000+ to earn a 3% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&Cs apply.	Trade stocks, ETFs and equity options commission-free, with access to futures, advanced charting tools, a robo-advisor and event trading powered by Kalshi.	Go to site More info	loading
Finder score 9.2 Excellent Interactive Brokers GlobalTrader	Finder score 9.2 Excellent	Stocks, Options, Mutual funds, ETFs, Cryptocurrency	$0	$0	3.83% Lite 4.83% Pro	Trade in a simulated trading environment and access a wide range of tradable assets.	Go to site More info	loading
Finder score 8.2 Great eToro	Finder score 8.2 Great	Stocks, Options, ETFs, Cryptocurrency, Investments	$0	$0	3.75%	No commission stock, ETF and options trades, with 3.9% interest on your options account balance and no options contract fees. See full disclosure.	Go to site More info	loading
Finder score 8 Great Acorns	Finder score 8 Great	Stocks, ETFs	$0	$0	N/A	Get a $20 bonus when you set up an account and make your first recurring investment (min. $5). T&Cs apply.	Automate investing with recurring contributions starting at $5 and invest spare change from everyday purchases.	Go to site More info	loading
Finder score 7.4 Great Stash	Finder score 7.4 Great	Stocks, ETFs	$0	$0	0.1%	Get $5 when you sign up and deposit $5. T&Cs apply.	Bank, automate your portfolio or invest in individual stocks and ETFs for as low as $3 per month.	Go to site More info	loading
Finder score 9 Excellent Wealthfront	Finder score 9 Excellent	Stocks, ETFs, High-yield cash account	$0	$500	3.75%	Get a $50 bonus when you sign up and fund a taxable automated investing account with at least $500. T&Cs apply.	Automate your stock and bond portfolio or trade individual stocks for as little as $1 apiece. Plus, earn 3.50% APY on your cash.	Go to site More info	loading
Finder score 7.2 Great J.P. Morgan Personal Advisors	Finder score 7.2 Great	Mutual funds, ETFs	$0	$25,000	N/A	Financial planning, advice and portfolio management. T&Cs apply.	Get ongoing access to an advisory team with personalized financial planning and expert-built portfolios. Provider terms & conditions apply	More info	loading
Finder score 8.2 Great M1 Finance	Finder score 8.2 Great	Stocks, ETFs, Cryptocurrency	$0	$100	4.00%	Build a custom portfolio of stocks and ETFs with automatic rebalancing. Plus, earn 4.00% APY with a high-yield cash account.	More info	loading

loading

Load More

Showing 12 of 12 results

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Alnylam Pharmaceuticals stock price (NASDAQ: ALNY)

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Alnylam Pharmaceuticals stock undervalued or overvalued?

Valuing Alnylam Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alnylam Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Alnylam Pharmaceuticals's P/E ratio

Alnylam Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1690x. In other words, Alnylam Pharmaceuticals shares trade at around 1690x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Alnylam Pharmaceuticals's EBITDA

Alnylam Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $321 million.

The EBITDA is a measure of a Alnylam Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Alnylam Pharmaceuticals share dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.

Alnylam Pharmaceuticals share price volatility

Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $205.87 up to $495.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 0.295. This would suggest that Alnylam Pharmaceuticals's shares are less volatile than average (for this exchange).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.

Frequently asked questions